Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339531 | 0.89 | MAP2K4 (0.34) | SLC22A12SLC16A3 | |
| SCHEMBL177327 | 0.86 | RORC (0.36) | SLC22A12SLC16A3HIF1AELANE | |
| SCHEMBL177258 | 0.85 | ELANE (0.35) | SLC22A12SLC16A3SLC16A1ELANE | |
| SCHEMBL178183 | 0.84 | SLC22A12 (0.36) | SLC22A12PLA2G10 | |
| SCHEMBL176949 | 0.84 | SLC22A12 (0.38) | SLC22A12SLC16A3ELANE | |
| SCHEMBL11897506 | 0.83 | CYP11B2 (0.36) | SLC22A12ALDH1A1HPGD | |
| SCHEMBL11897199 | 0.81 | CYP11B2 (0.33) | SLC22A12SLC16A3HIF1ASLC16A1ALDH1A1 | |
| SCHEMBL257418 | 0.76 | RORC (0.34) | KDM4EALDH1A1 | |
| SCHEMBL177174 | 0.75 | MAP2K4 (0.39) | ELANE | |
| SCHEMBL2238954 | 0.75 | SLC22A12 (0.35) | SLC22A12SLC16A3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | SLC22A12 2079/4885SLC16A3 2417/4885HIF1A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.